Statistical analysis
fever
RECRUITMENT
For each studied intervention the sample size was adaptive based on prespecified futility and success stopping rules (The rate of viral clearance was expressed as a slope coefficient and estimated under a Bayesian hierarchical linear model (random effect terms for the individual patient slope and intercept).Comparison of times to resolution of fever and resolution of symptoms between different treatment groups used the log-rank test. For the analysis of viral rebound, comparison of proportions was done using the Fisher exact test.Each studied intervention was compared only against its concurrent control, with interim analyses planned every additional ten patients recruited per group. In practice, the interim analyses were less frequent than planned as recruitment occurred very rapidly. Initially, all interim analyses compare the new intervention against the no study drug group. The intervention is dropped for futility when there is probability greater than 0·9 that the acceleration in viral clearance is less than 20% (this threshold was increased from 12·5% in January, 2023, statistical analysis plan version 3.0). If the new intervention reaches the success threshold (ie, probability >0·9 of acceleration in viral clearance >20% relative to no study drug), it is then compared with the positive control. This comparison terminates when the intervention is shown to be inferior, non-inferior, or superior to the positive control group using a 10% non-inferiority margin. If the intervention is superior, it then replaces the positive control group (All efficacy analyses were done in a modified intention-to-treat population, comprising patients who had more than 2 days of follow-up data. Safety was analysed in all patients who received at least one dose of the study drug. A sensitivity analysis was performed using a non-linear model fitted to the serial viral densities, which allows for an initial increase followed by a log-linear decrease (exact specification is given in the The ongoing platform trial is registered at 